Literature DB >> 11163634

Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

G Cossu1, C Ledent, L Fattore, A Imperato, G A Böhme, M Parmentier, W Fratta.   

Abstract

The rewarding effects of morphine, cocaine, amphetamine and nicotine were evaluated in CB1 receptor knockout mice by means of an intravenous self-administration model. Experiments were carried out on drug-naive animals using a nose-poking response (NPR)-like as operandum. The results of the present study indicate that morphine did not induce intravenous self-administration in mutant CB1 receptor knockout mice, whereas it was significantly self-administered by the corresponding wild type mice. On the contrary, cocaine, amphetamine and nicotine were self-administered to the same extent by both wild type and CB1 receptor knockout mice. These data clearly indicate that the CB1 cannabinoid receptor is essential not only for the expression of cannabinoid reinforcing effects but also for the modulation of morphine rewarding effects. The specificity of such interaction is supported by the finding that contrary to morphine, cocaine, d-amphetamine and nicotine were self-administered by mice at the same extent either in presence or in absence of the CB1 receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163634     DOI: 10.1016/s0166-4328(00)00311-9

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  78 in total

Review 1.  Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice.

Authors:  G Kunos; S Bátkai
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

2.  Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.

Authors:  Daniela Braida; Mariaelvina Sala
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

3.  Is cannabinoid transmission involved in rewarding properties of drugs of abuse?

Authors:  Daniela Parolaro; Tiziana Rubino
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 4.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

5.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

Review 6.  [Future medications for tobacco and cannabis dependence].

Authors:  Bernard Le Foll; Zuzana Justinova; Gianlugi Tanda; Steven R Goldberg
Journal:  Bull Acad Natl Med       Date:  2008-01       Impact factor: 0.144

7.  Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

Authors:  D Proudnikov; T Kroslak; J C Sipe; M Randesi; D Li; S Hamon; A Ho; J Ott; M J Kreek
Journal:  Pharmacogenomics J       Date:  2009-12-15       Impact factor: 3.550

8.  CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

Authors:  M Sabrina Spano; Liana Fattore; Gregorio Cossu; Serena Deiana; Paola Fadda; Walter Fratta
Journal:  Br J Pharmacol       Date:  2004-08-31       Impact factor: 8.739

9.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

Review 10.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.